Cite
Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
MLA
Xian, Linfeng, et al. “Heterogeneity, Inherent and Acquired Drug Resistance in Patient-Derived Organoid Models of Primary Liver Cancer.” Cellular Oncology (2211-3428), vol. 45, no. 5, Oct. 2022, pp. 1019–36. EBSCOhost, https://doi.org/10.1007/s13402-022-00707-3.
APA
Xian, L., Zhao, P., Chen, X., Wei, Z., Ji, H., Zhao, J., Liu, W., Li, Z., Liu, D., Han, X., Qian, Y., Dong, H., Zhou, X., Fan, J., Zhu, X., Yin, J., Tan, X., Jiang, D., Yu, H., & Cao, G. (2022). Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer. Cellular Oncology (2211-3428), 45(5), 1019–1036. https://doi.org/10.1007/s13402-022-00707-3
Chicago
Xian, Linfeng, Pei Zhao, Xi Chen, Zhimin Wei, Hongxiang Ji, Jun Zhao, Wenbin Liu, et al. 2022. “Heterogeneity, Inherent and Acquired Drug Resistance in Patient-Derived Organoid Models of Primary Liver Cancer.” Cellular Oncology (2211-3428) 45 (5): 1019–36. doi:10.1007/s13402-022-00707-3.